Prevention of Damage Induced by Facial Mask Ventilation
NCT ID: NCT01351155
Last Updated: 2014-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
252 participants
INTERVENTIONAL
2011-12-31
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
However, precise data are lacking about the demonstration of the effectiveness of these devices and the possibility of using other protective devices.
The purpose of this study was to evaluate the usefulness of large-scale three different systems of protection vs. no protection in preventing the development of decubitus lesions in patients receiving NIV for an episode of ARF.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Severe skin injury with ulceration and necrosis occurs in approximately 10% of patients receiving NIV trained in services. In the multicenter evaluation of a new face mask dedicated to the NIV (Gregoretti et al, Intens Care Med 2002) describes the development of NIV-induced decubitus in 100% of the control group treated with masks "traditional", with an average grade of 2.79 on a scale of Assessment Standard ranging from 1 (erythema) to 4 (necrosis).
The strategy of prevention and treatment commonly adopted is the application of appropriately shaped hydrocolloids. However, the data relating to the use of protective systems for the prevention of NIV-induced decubitus are limited and controversial. In a first pilot study (Callaghan et al,Professional Nurse 1998, the authors compared the protective efficacy of two types of "dressing" (Granuflex, Spenco Dermal and 10 patients, 10 patients) vs a non-randomized control group (10 patients): 30 patients in total . In this work, which presents a problem of inter-observer variability, the "Granuflex group" (or Duoderm) showed a greater protective effect (3 vs. 7 lesions in "Spenco Dermal group" vs 9 lesions in the control group). Recently, in a larger study, Weng (Intensive Crit Care Nurs 2008) compared the efficacy of two devices (Tegaderm and tegasorb) vs. a control group in 90 patients (30 per group) undergoing NIV. The rate of lesions was significantly lower in the treated groups (53% Tegaderm; Tegasorb 40%) than in the control group (96.7%), with no significant difference between the two interventional arms on both the incidence and the timing of onset of injury.
Therefore, given the limited data currently available regarding both the effectiveness and the choice of a protective device and in consideration of the continuous expansion of NIV in the acute setting, in our opinion it's seems to us justified to perform a controlled study comparing different types of devices in terms of skin protection during NIV.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
polyurethane foam (Allewyn adesive)
Polyurethane foam is applied as skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
Skin protective dressing device
Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury
polyurethane film (Tegaderm)
The polyurethane film is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
Skin protective dressing device
Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury
Hydrocolloid (Duoderm)
Hydrocolloid is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
Skin protective dressing device
Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury
Control
In this no-intervention arm, any skin protective dressing devices is applied before NIV starting
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Skin protective dressing device
Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. pH\<7.30,
2. PaCO2\>50 mmHg,
3. PaO2/FiO2\<250,
4. respiratory rate\>25/min and use of accessory respiratory muscles
* Pure Hypoxemic acute respiratory failure(while in O2-therapy):
1. pH\>7.35
2. PaCO2\< 50 mmHg
3. PaO2/FiO2\<250
4. respiratory rate\>25/min and use of accessory respiratory muscles
For both types of acute respiratory failure: Signed informed consent by the patient or next keen. Age more than 20 year's old
Exclusion Criteria
2. severe hemodynamic instability (\> 1 vasoactive amine for more than 24 hours)
3. acute coronary syndrome (instable angina/AMI)
4. refusal of NIV
5. anatomic abnormalities interfering with mask fitting
6. pre-existent nasal lesions;
7. NIV for\< 24 hours
8. kwon hypersensitivity to hydrocolloid and polyurethane
9. cancel of informed consent
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Smith & Nephew, Inc.
INDUSTRY
Italian Association of Hospital Pneumologists
OTHER
Ospedale San Donato
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Raffaele Scala
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Raffaele Scala, MD, FCCP
Role: STUDY_CHAIR
PULMONARY DIVISION WITH RESPIRATORY INTENSIVE CARE UNIT, S. DONATO HOSPITAL, AREZZO, ITALY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pulmonary Division With Respiratory Intensive Care Unit, S. Donato Hospital, Arezzo, Italy
Lucca, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Weng MH. The effect of protective treatment in reducing pressure ulcers for non-invasive ventilation patients. Intensive Crit Care Nurs. 2008 Oct;24(5):295-9. doi: 10.1016/j.iccn.2007.11.005. Epub 2008 Feb 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RSAIPO2011
Identifier Type: -
Identifier Source: org_study_id